Cargando…

Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer

BACKGROUND: Myeloid derived suppressor cells (MDSC) are important regulators of immune responses. We evaluated the mechanistic role of MDSC depletion on antigen presenting cell (APC), NK, T cell activities and therapeutic vaccination responses in murine models of lung cancer. PRINCIPAL FINDINGS: Ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Srivastava, Minu K., Zhu, Li, Harris-White, Marni, Kar, Upendra, Huang, Min, Johnson, Ming F., Lee, Jay M., Elashoff, David, Strieter, Robert, Dubinett, Steven, Sharma, Sherven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398024/
https://www.ncbi.nlm.nih.gov/pubmed/22815789
http://dx.doi.org/10.1371/journal.pone.0040677
_version_ 1782238233909788672
author Srivastava, Minu K.
Zhu, Li
Harris-White, Marni
Kar, Upendra
Huang, Min
Johnson, Ming F.
Lee, Jay M.
Elashoff, David
Strieter, Robert
Dubinett, Steven
Sharma, Sherven
author_facet Srivastava, Minu K.
Zhu, Li
Harris-White, Marni
Kar, Upendra
Huang, Min
Johnson, Ming F.
Lee, Jay M.
Elashoff, David
Strieter, Robert
Dubinett, Steven
Sharma, Sherven
author_sort Srivastava, Minu K.
collection PubMed
description BACKGROUND: Myeloid derived suppressor cells (MDSC) are important regulators of immune responses. We evaluated the mechanistic role of MDSC depletion on antigen presenting cell (APC), NK, T cell activities and therapeutic vaccination responses in murine models of lung cancer. PRINCIPAL FINDINGS: Individual antibody mediated depletion of MDSC (anti-Gr1 or anti-Ly6G) enhanced the antitumor activity against lung cancer. In comparison to controls, MDSC depletion enhanced the APC activity and increased the frequency and activity of the NK and T cell effectors in the tumor. Compared to controls, the anti-Gr1 or anti-Ly6G treatment led to increased: (i) CD8 T cells, (ii) NK cells, (iii) CD8 T or NK intracytoplasmic expression of IFNγ, perforin and granzyme (iv) CD3 T cells expressing the activation marker CD107a and CXCR3, (v) reduced CD8 T cell IL-10 production in the tumors (vi) reduced tumor angiogenic (VEGF, CXCL2, CXCL5, and Angiopoietin1&2) but enhanced anti-angiogenic (CXCL9 and CXCL10) expression and (vii) reduced tumor staining of endothelial marker Meca 32. Immunocytochemistry of tumor sections showed reduced Gr1 expressing cells with increased CD3 T cell infiltrates in the anti-Gr1 or anti-Ly6G groups. MDSC depletion led to a marked inhibition in tumor growth, enhanced tumor cell apoptosis and reduced migration of the tumors from the primary site to the lung compared to controls. Therapeutic vaccination responses were enhanced in vivo following MDSC depletion with 50% of treated mice completely eradicating established tumors. Treated mice that rejected their primary tumors acquired immunological memory against a secondary tumor challenge. The remaining 50% of mice in this group had 20 fold reductions in tumor burden compared to controls. SIGNIFICANCE: Our data demonstrate that targeting MDSC can improve antitumor immune responses suggesting a broad applicability of combined immune based approaches against cancer. This multifaceted approach may prove useful against tumors where MDSC play a role in tumor immune evasion.
format Online
Article
Text
id pubmed-3398024
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33980242012-07-19 Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer Srivastava, Minu K. Zhu, Li Harris-White, Marni Kar, Upendra Huang, Min Johnson, Ming F. Lee, Jay M. Elashoff, David Strieter, Robert Dubinett, Steven Sharma, Sherven PLoS One Research Article BACKGROUND: Myeloid derived suppressor cells (MDSC) are important regulators of immune responses. We evaluated the mechanistic role of MDSC depletion on antigen presenting cell (APC), NK, T cell activities and therapeutic vaccination responses in murine models of lung cancer. PRINCIPAL FINDINGS: Individual antibody mediated depletion of MDSC (anti-Gr1 or anti-Ly6G) enhanced the antitumor activity against lung cancer. In comparison to controls, MDSC depletion enhanced the APC activity and increased the frequency and activity of the NK and T cell effectors in the tumor. Compared to controls, the anti-Gr1 or anti-Ly6G treatment led to increased: (i) CD8 T cells, (ii) NK cells, (iii) CD8 T or NK intracytoplasmic expression of IFNγ, perforin and granzyme (iv) CD3 T cells expressing the activation marker CD107a and CXCR3, (v) reduced CD8 T cell IL-10 production in the tumors (vi) reduced tumor angiogenic (VEGF, CXCL2, CXCL5, and Angiopoietin1&2) but enhanced anti-angiogenic (CXCL9 and CXCL10) expression and (vii) reduced tumor staining of endothelial marker Meca 32. Immunocytochemistry of tumor sections showed reduced Gr1 expressing cells with increased CD3 T cell infiltrates in the anti-Gr1 or anti-Ly6G groups. MDSC depletion led to a marked inhibition in tumor growth, enhanced tumor cell apoptosis and reduced migration of the tumors from the primary site to the lung compared to controls. Therapeutic vaccination responses were enhanced in vivo following MDSC depletion with 50% of treated mice completely eradicating established tumors. Treated mice that rejected their primary tumors acquired immunological memory against a secondary tumor challenge. The remaining 50% of mice in this group had 20 fold reductions in tumor burden compared to controls. SIGNIFICANCE: Our data demonstrate that targeting MDSC can improve antitumor immune responses suggesting a broad applicability of combined immune based approaches against cancer. This multifaceted approach may prove useful against tumors where MDSC play a role in tumor immune evasion. Public Library of Science 2012-07-16 /pmc/articles/PMC3398024/ /pubmed/22815789 http://dx.doi.org/10.1371/journal.pone.0040677 Text en This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Srivastava, Minu K.
Zhu, Li
Harris-White, Marni
Kar, Upendra
Huang, Min
Johnson, Ming F.
Lee, Jay M.
Elashoff, David
Strieter, Robert
Dubinett, Steven
Sharma, Sherven
Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
title Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
title_full Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
title_fullStr Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
title_full_unstemmed Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
title_short Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
title_sort myeloid suppressor cell depletion augments antitumor activity in lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398024/
https://www.ncbi.nlm.nih.gov/pubmed/22815789
http://dx.doi.org/10.1371/journal.pone.0040677
work_keys_str_mv AT srivastavaminuk myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT zhuli myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT harriswhitemarni myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT karupendra myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT huangmin myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT johnsonmingf myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT leejaym myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT elashoffdavid myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT strieterrobert myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT dubinettsteven myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT sharmasherven myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer